DK0909315T3 - CCK-2, en receptortyrosinkinase - Google Patents

CCK-2, en receptortyrosinkinase

Info

Publication number
DK0909315T3
DK0909315T3 DK95900749T DK95900749T DK0909315T3 DK 0909315 T3 DK0909315 T3 DK 0909315T3 DK 95900749 T DK95900749 T DK 95900749T DK 95900749 T DK95900749 T DK 95900749T DK 0909315 T3 DK0909315 T3 DK 0909315T3
Authority
DK
Denmark
Prior art keywords
mck
receptor tyrosine
relates
tyrosine kinase
cck
Prior art date
Application number
DK95900749T
Other languages
English (en)
Inventor
Axel Ullrich
Frauke H E Alves
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22547060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0909315(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0909315T3 publication Critical patent/DK0909315T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95900749T 1993-11-16 1994-11-16 CCK-2, en receptortyrosinkinase DK0909315T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/153,397 US6051397A (en) 1993-11-16 1993-11-16 DNA encoding MCK-10, a novel receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
DK0909315T3 true DK0909315T3 (da) 2005-09-12

Family

ID=22547060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900749T DK0909315T3 (da) 1993-11-16 1994-11-16 CCK-2, en receptortyrosinkinase

Country Status (10)

Country Link
US (4) US6051397A (da)
EP (1) EP0909315B1 (da)
AT (1) ATE296351T1 (da)
AU (2) AU8143894A (da)
CA (1) CA2187152A1 (da)
DE (1) DE69434385T2 (da)
DK (1) DK0909315T3 (da)
ES (1) ES2242956T3 (da)
PT (1) PT909315E (da)
WO (2) WO1995014088A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627733B2 (en) 1993-06-14 2003-09-30 Jeffrey D. Johnson Receptor tyrosine kinase with a discoidin-type binding domain
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6022694A (en) * 1997-04-04 2000-02-08 Regeneron Pharmaceuticals, Inc. Assay for ligands to tyrosine kinase receptors
US6482607B1 (en) * 1998-06-16 2002-11-19 Rmf Dictagene S.A. Expression vector for use in a one-step purification protocol
GB9820392D0 (en) 1998-09-19 1998-11-11 Eastman Kodak Co Novel yellow couplers providing images with improved sharpness and photographic elements containing them
AUPQ873300A0 (en) * 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
WO2001019847A1 (en) * 1999-09-15 2001-03-22 Medvet Science Pty Ltd A binding motif of a receptor
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US6365355B1 (en) 2000-03-28 2002-04-02 The Regents Of The University Of California Chimeric proteins for detection and quantitation of DNA mutations, DNA sequence variations, DNA damage and DNA mismatches
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046416A2 (en) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20070025997A1 (en) * 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
DK1675961T3 (da) * 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
US20090142345A1 (en) * 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
WO2008070090A2 (en) * 2006-12-05 2008-06-12 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2518157A1 (en) 2011-04-26 2012-10-31 Sanofi Test Systems and methods for identifying a compound altering cellular DDR activity
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013155365A1 (en) * 2012-04-12 2013-10-17 University Of Maryland Markers for diagnosing amyotrophic lateral sclerosis
HK1212348A1 (en) 2012-12-19 2016-06-10 Novartis Ag Autotaxin inhibitors
KR101462329B1 (ko) 2013-01-30 2014-11-21 중앙대학교 산학협력단 디스코이딘 도메인 리셉터 2의 ｊｍ2 도메인의 발현 촉진제를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
MX368059B (es) 2013-07-18 2019-09-18 Novartis Ag Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica.
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
WO2019071262A1 (en) * 2017-10-06 2019-04-11 The Regents Of The University Of California RAPID SITU DETECTION OF DNA AND RNA
US20230130372A1 (en) 2019-12-17 2023-04-27 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004606A (en) * 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
NL8900529A (nl) 1989-03-03 1990-10-01 Eurodiagnostics B V Werkwijze en kit voor het bepalen van tyrosine fosforylerende en defosforylerende activiteit.
CA2062377A1 (en) 1991-03-21 1992-09-22 Mariano Barbacid Method for detection of neuroactive substances
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse

Also Published As

Publication number Publication date
US6897029B1 (en) 2005-05-24
AU8143894A (en) 1995-06-06
DE69434385D1 (de) 2005-06-30
WO1995014089A3 (en) 1995-06-15
WO1995014088A1 (en) 1995-05-26
US20060147372A1 (en) 2006-07-06
CA2187152A1 (en) 1995-05-26
ES2242956T3 (es) 2005-11-16
US6051397A (en) 2000-04-18
AU8143994A (en) 1995-06-06
WO1995014089A2 (en) 1995-05-26
DE69434385T2 (de) 2006-05-24
EP0909315A2 (en) 1999-04-21
PT909315E (pt) 2005-10-31
US5677144A (en) 1997-10-14
ATE296351T1 (de) 2005-06-15
EP0909315B1 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
DK0909315T3 (da) CCK-2, en receptortyrosinkinase
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
AP1486A (en) Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use.
AP2001002341A0 (en) Diaminothiazoles and their use for inhibiting protein kinases.
DE69232537D1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
MXPA06001193A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.
CU23126A3 (es) Inhibicion de kinasa raf usando ureas heterociclicas sustituidas
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
AU4761100A (en) Methods and materials for generating sh3 domains with tailored binding properties
BR0111869A (pt) Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
CO4700426A1 (es) Ligandos especificos del neuropeptido y1
EP1383919A4 (en) METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS MACROPHAGE MIGRATION INHIBITION FACTOR RECEPTOR
NO177214C (no) Anordning ved en stol som omfatter understöttende og fjærende elementer som tillater ettergivende bevegelse av stolen i forhold til et underlag
Szelenyi et al. Contribution of Differently Localized α2‐and β‐Adrenoceptors in the Modulation of TNF‐α and IL‐10 Production in Endotoxemic Mice
ATE279515T1 (de) Pct-65 serotonin rezeptor
ES2074332T3 (es) Derivados de polihidroxiciclopentano, su preparacion y su uso terapeutico.
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
DE69515645D1 (de) Cd69 - transkriptionsregulierende elemente
ATE252636T1 (de) Klonierung und expression von dem beta app-c100 rezeptor
GB9607249D0 (en) Compounds
ATE226446T1 (de) Muteine von wildtyp-cytokinen und ihre verwendung als immunogene